| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expense), net | 30,681 | 5,026 | ||
| Net income (loss) from continuing operations | 8,204 | -19,855 | ||
| Net income from discontinued operations, net of tax | 0 | 0 | ||
| Net income (loss) | 8,204 | -19,855 | ||
| Net loss per share attributable to common stockholders - basic | 0.94 | -2.27 | ||
| Net loss per share attributable to common stockholders - diluted | 0.94 | -2.27 | ||
| Weighted average number of shares outstanding, diluted | 8,771,519 | 8,743,733 | ||
| Weighted-average shares outstanding - basic | 8,758,692 | 8,743,733 | ||
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)